Previous 10 | Next 10 |
BridgeBio Pharma (NASDAQ:BBIO) executed a definitive credit facility agreement with a syndicate of lenders for up to $750M in financing which replaces its $100M debt facility with Hercules. Of the total, $450M was funded on Nov.17 while additional $300M will be funded at company's option...
-Innovative financing facility and existing cash balance gives BridgeBio access to over $1.2 billion, which is expected to fully fund the Company’s 30+ genetic disease and cancer pipeline programs into 2024 PALO ALTO, Calif., Nov. 18, 2021 (GLOBE NEWSWIRE) -- BridgeBio Phar...
This portfolio strategy uses the quarterly 13F filings to extract 50 consensus stocks from 40 large hedge funds that have more than $3.5 billion Assets Under Management. After the Q2-2021 13F filings, the consensus holdings were updated, 6 stocks were removed and 6 added from the univ...
BridgeBio Pharma (NASDAQ:BBIO): Q3 GAAP EPS of -$1.06 misses by $0.13. Revenue of $2.34M (-71.2% Y/Y) misses by $13.78M. Press Release For further details see: BridgeBio Pharma EPS misses by $0.13, misses on revenue
BridgeBio Pharma Reports Third Quarter 2021 Financial Results and Business Update --Topline results from Part A of the Phase 3 ATTRibute-CM trial of TTR stabilizer for transthyretin amyloid cardiomyopathy (ATTR-CM) expected by end of 2021 --Meaningful progress in RAS cancer ...
BridgeBio Pharma (NASDAQ:BBIO) announces that the first patient has been dosed in the company's Phase 1/2 trial of BBP-812, an investigational adeno-associated virus (AAV) 9 gene therapy for the treatment of Canavan disease. Canavan disease is an ultra-rare and fatal disease that affects...
BridgeBio Pharma Announces Dosing of First Patient in Phase 1/2 Trial of Investigational Gene Therapy for Canavan Disease <span class="legendSpanClass">-If successful, BridgeBio's gene therapy could be the first approved therapeutic option for children born with Canavan di...
This portfolio strategy uses the quarterly 13F filings to extract 50 consensus stocks from 40 large hedge funds that have more than $3.5 billion in Assets Under Management. After the Q2-2021 13F filings, the consensus holdings were updated, 6 stocks were removed and 6 added from the u...
BridgeBio Pharma (NASDAQ:BBIO) announces two new academic collaborations with Columbia University and Mount Sinai to translate cutting-edge research discoveries into potential therapies for patients with genetic diseases and genetically driven cancers. The company has initiated 25 s...
BridgeBio Pharma Announces Collaborations with Columbia University and Mount Sinai to Develop Potential Therapies for Genetic Diseases and Cancers - The new agreements mean BridgeBio has collaborations with 25 leading academic institutions focused on genetic disease and precisio...
News, Short Squeeze, Breakout and More Instantly...
PALO ALTO, Calif., July 23, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases, announced that Thomas Trimarchi, Ph.D., has been appointed President and...
2024-07-09 22:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-20 00:42:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...